author-photo

Kyle Edgar

Genentech

23

Papers

1040

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (2)
Abstract PR03: Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors

2020 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (12)
Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
Quantitative phosphoproteomic analysis of the PI3K‐regulated signaling network

2016 Proteomics
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 2672: Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract B37: Mechanisms of acquired resistance to the PI3K inhibitor GDC-0941 in breast cancer cell lines

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.

2013 Oncogene
Show All
- Source
- Cite
- Save
Citations (63)
Oncogenic ERBB3 Mutations in Human Cancers

2013 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (270)
Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)